Organ failure · Severe acute pancreatitis
It is very uncertain whether nasogastric changes organ failure (single or multiple) compared with nasojejunal tube feeding (very low certainty).
1 finding from 1 review
Rate of infection (local or systemic) · Severe acute pancreatitis
It is very uncertain whether nasogastric changes rate of infection (local or systemic) compared with nasojejunal tube feeding (very low certainty).
1 finding from 1 review
Success of the procedure · Severe acute pancreatitis
It is very uncertain whether nasogastric changes success rate of the procedure compared with nasojejunal tube feeding (very low certainty).
1 finding from 1 review
Procedure‐related general complications · Severe acute pancreatitis
It is very uncertain whether nasogastric changes complications associated with the procedure compared with nasojejunal tube feeding (very low certainty).
1 finding from 1 review
Surgical intervention · Severe acute pancreatitis
It is very uncertain whether nasogastric changes surgical intervention compared with nasojejunal tube feeding (very low certainty).
1 finding from 1 review
Requirement for parenteral nutrition · Severe acute pancreatitis
It is very uncertain whether nasogastric changes requirement for parenteral nutrition compared with nasojejunal tube feeding (very low certainty).
1 finding from 1 review
Global state: no improvement ‐ medium termAs defined in each study · patients with schizophrenia
It is very uncertain whether pericyazine changes global state ‐ not improved compared with typical antipsychotic (very low certainty).
1 finding from 1 review
Mental state ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Leaving the study early for specific reasons · patients with schizophrenia
It is very uncertain whether pericyazine changes leaving the study early for specific reasons compared with atypical antipsychotic (very low certainty).
1 finding from 1 review
Behaviour ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Economic outcome ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Relapse · patients with schizophrenia
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
It is very uncertain whether pericyazine changes adverse events ‐ for specific reasons ‐ Extrapyramidal side effect compared with typical antipsychotic (very low certainty).
1 finding from 1 review
Mental state ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Leaving the study early for specific reasons · patients with schizophrenia
It is very uncertain whether pericyazine changes leaving the study early for specific reasons compared with typical antipsychotic (very low certainty).
1 finding from 1 review
Behaviour ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Economic outcome ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Global state: no improvement ‐ medium termAs defined in each study · patients with schizophrenia
It is very uncertain whether pericyazine changes global state ‐ not improved compared with atypical antipsychotic (very low certainty).
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
It is very uncertain whether pericyazine changes adverse Effects ‐ Extrapyramidal symptoms compared with atypical antipsychotic (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with obesity
1 finding from 1 review